A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive advanced castration-resistant prostate cancer (CRPC) Meeting Abstract


Authors: Rathkopf, D. E.; Danila, D. C.; Slovin, S. F.; Morris, M. J.; Steinbrecher, J. E.; Chen, Y.; Fleisher, M.; Larson, S. M.; Sawyers, C. L.; Scher, H. I.
Abstract Title: A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive advanced castration-resistant prostate cancer (CRPC)
Meeting Title: 47th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 29
Issue: 15 Suppl.
Meeting Dates: 2011 Jun 3-7
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2011-05-20
Language: English
ACCESSION: WOS:000208880304615
DOI: 10.1200/jco.2011.29.15_suppl.tps190
PROVIDER: wos
Notes: Meeting Abstract: TPS190 -- Source: Wos
Altmetric Score
MSK Authors
  1. Charles L Sawyers
    157 Sawyers
  2. Susan Slovin
    186 Slovin
  3. Michael Morris
    280 Morris
  4. Yu Chen
    68 Chen
  5. Dana Elizabeth Rathkopf
    144 Rathkopf
  6. Steven M Larson
    779 Larson
  7. Martin Fleisher
    242 Fleisher
  8. Howard Scher
    835 Scher
  9. Daniel C Danila
    83 Danila